Search Results for ""drugs for""
Search again or select article below to purchase. Single article price: $45. Order 3 or more at one time and receive a 10% discount.
Sort by relevance | Sort by date
Searched for "drugs for". Results 421 to 430 of 614 total matches.
In Brief: New Recommendations for Gonococcal Infection
The Medical Letter on Drugs and Therapeutics • May 03, 2021 (Issue 1623)
to a reevaluation of this guidance. Use
of the higher ceftriaxone dose increases the amount of
time that free drug ...
The CDC has issued new recommendations for
treatment of gonococcal infection. A single 500-mg
IM dose (1000 mg in patients weighing ≥150 kg) of the
third-generation cephalosporin ceftriaxone is now the
treatment of choice for patients with uncomplicated
urogenital, rectal, or pharyngeal gonorrhea.
In Brief: Subcutaneous Ocrelizumab (Ocrevus Zunovo) for Multiple Sclerosis
The Medical Letter on Drugs and Therapeutics • Oct 28, 2024 (Issue 1714)
drugs for
treatment of MS. Ocrelizumab remains the only drug
approved for treatment of primary ...
Ocrevus Zunovo (Genentech), a subcutaneous (SC)
formulation of the anti-CD20 monoclonal antibody
ocrelizumab plus human recombinant hyaluronidase-ocsq
has been approved by the FDA for treatment of
primary progressive and relapsing forms of multiple
sclerosis (MS). Intravenous ocrelizumab (Ocrevus),
which was approved for the same indications in 2017,
is one of the most commonly prescribed drugs for
treatment of MS. Ocrelizumab remains the only drug
approved for treatment of primary progressive MS.
Med Lett Drugs Ther. 2024 Oct 28;66(1714):174 doi:10.58347/tml.2024.1714b | Show Introduction Hide Introduction
An EUA for Sotrovimab for Treatment of COVID-19
The Medical Letter on Drugs and Therapeutics • Jun 28, 2021 (Issue 1627)
with the drug.4
An EUA for Sotrovimab for
Treatment of COVID-19
CoV-2. Its exact mechanism of action ...
The investigational monoclonal antibody sotrovimab
(VIR-7831; GSK/Vir Biotechnology) has been granted
an FDA Emergency Use Authorization (EUA) for
treatment of mild to moderate COVID-19 in patients
≥12 years old who weigh ≥40 kg and are at high
risk of progressing to severe disease, including
hospitalization and death.1 Two other monoclonal
antibody regimens are authorized for the same
indication: casirivimab (REGN10933) and imdevimab
(REGN10987) administered together, and bamlanivimab (LY-CoV555) and etesevimab (LYCoV016)
administered together.
The FDA revoked its EUA...
Ceftobiprole Medocaril (Zevtera) — A New Cephalosporin Antibiotic
The Medical Letter on Drugs and Therapeutics • Sep 15, 2025 (Issue 1737)
cephalosporin
antibacterial drug, has been approved by the FDA for
treatment of Staphylococcus aureus ...
Ceftobiprole medocaril sodium (Zevtera – Innoviva
Specialty Therapeutics), a new IV cephalosporin
antibacterial drug, has been approved by the FDA for
treatment of Staphylococcus aureus bacteremia (SAB),
including right-sided infective endocarditis, acute
bacterial skin and skin structure infections (ABSSSIs),
and community-acquired bacterial pneumonia (CABP)
(see Table 1). It is the second cephalosporin with
activity against methicillin-resistant S. aureus (MRSA)
to be approved in the US; ceftaroline (Teflaro), which
was approved for treatment of ABSSSIs and CABP in
2010, was the...
Med Lett Drugs Ther. 2025 Sep 15;67(1737):149-52 doi:10.58347/tml.2025.1737d | Show Introduction Hide Introduction
COVID-19 Updates
The Medical Letter on Drugs and Therapeutics • Jan 24, 2022 (Issue 1642)
on vaccines and drugs for COVID-19 can
be found in the COVID-19 Resources section of our website ...
On January 3, the FDA amended its Emergency
Use Authorization (EUA) for the Pfizer-BioNTech
COVID-19 vaccine (Comirnaty) to incorporate the
following changes. The anti-SARS-CoV-2 antibody combinations
casirivimab plus imdevimab (REGEN-COV) and
bamlanivimab plus etesevimab are not active
against the Omicron variant of SARS-CoV-2.
Lurbinectedin (Zepzelca) for Small-Cell Lung Cancer (online only)
The Medical Letter on Drugs and Therapeutics • Nov 14, 2022 (Issue 1663)
, and hepatotoxity are
common with use of the drug.
PREGNANCY AND LACTATION — In animal studies,
administration ...
The alkylating agent lurbinectedin (Zepzelca – Jazz)
has received accelerated approval from the FDA
for treatment of metastatic small-cell lung cancer
(SCLC) in adults with disease progression on or after
platinum-based chemotherapy. Accelerated approval
was based on the overall response rate and duration
of response. About 13-15% of lung cancers are small-cell
cancers. Most SCLCs occur in patients who are
current or former smokers.
Amivantamab (Rybrevant) for Non-Small Cell Lung Cancer (online only)
The Medical Letter on Drugs and Therapeutics • Nov 14, 2022 (Issue 1663)
.
Accelerated approval of the drug was based on the
overall response rate and duration of response ...
Amivantamab-vmjw (Rybrevant – Janssen), an EGFR-MET
bispecific antibody, has received accelerated
approval from the FDA for IV treatment of locally
advanced or metastatic non-small cell lung cancer
(NSCLC) with epidermal growth factor receptor
(EGFR) exon 20 insertion mutations in adults whose
disease has progressed on or after platinum-based
chemotherapy. It is the first bispecific antibody
to become available in the US for this indication.
Accelerated approval of the drug was based on the
overall response rate and duration of response.
Sulbactam/Durlobactam (Xacduro) for Acinetobacter Pneumonia
The Medical Letter on Drugs and Therapeutics • Nov 27, 2023 (Issue 1690)
drugs, including carbapenems.1 Polymyxins B and E (colistin) have been used as salvage therapy ...
The FDA has approved Xacduro (Innoviva), a
combination of the beta-lactam antibacterial
sulbactam and the beta-lactamase inhibitor
durlobactam, for IV treatment of adults with hospital-acquired
or ventilator-associated bacterial pneumonia
caused by susceptible isolates of Acinetobacter
baumannii-calcoaceticus complex (ABC).
Med Lett Drugs Ther. 2023 Nov 27;65(1690):189-90 doi:10.58347/tml.2023.1690c | Show Introduction Hide Introduction
Comparison Table: Some Nonopioid Analgesics for Pain (online only)
The Medical Letter on Drugs and Therapeutics • Mar 07, 2022 (Issue 1645)
Comparison Table: Some Nonopioid Analgesics for Pain
Drug Some Available Formulations Usual Adult ...
View the Comparison Table: Some Nonopioid Analgesics for Pain
Addendum: Over-the-Counter Narcan Nasal Spray
The Medical Letter on Drugs and Therapeutics • Oct 02, 2023 (Issue 1686)
entitled Drugs for
Opioid Use Disorder and In Brief: Over-the-Counter
Narcan Nasal Spray earlier ...
Since the publication of our articles entitled Drugs for
Opioid Use Disorder and In Brief: Over-the-Counter
Narcan Nasal Spray earlier this year, Narcan (Emergent),
a nasal spray that delivers 4 mg of the opioid antagonist
naloxone, has become available for sale over the counter
(OTC). According to the manufacturer, the retail price for
a box containing 2 doses is $44.99. Some insurance
companies have announced plans to cover OTC
purchase of the drug for their members.
Med Lett Drugs Ther. 2023 Oct 2;65(1686):160 doi:10.58347/tml.2023.1686f | Show Introduction Hide Introduction